Transgenic Animals for Studying Regulation of Genes

Background of the Invention

Vascular endothelial cell (EC) activation is one of the first events in inflammatory conditions and transplant rejection. A specific marker of EC activation is E-selectin.

5 Expression of this gene is generally absent under resting conditions and induced by inflammatory stimuli, as well as being NF-kB dependent. Expression is restricted to the endothelium.

Immunohistochemistry is a standard technique by which signalling events involved

10 in disorders associated with inflammatory, thrombotic, ischaemic or neoplastic conditions or transplant rejection, can be assessed; and, for example, E-selectin expression can be readily studied by this method in vitro. However, monitoring of E-selectin expression in vivo has been limited to immunohistochemistry of biopsies or post-mortem specimens. There has been a need by workers in the art for an in vivo model allowing assessment of

15 E-selectin expression in a live subject.

Summary of the Invention

The present invention relates to an animal model useful for screening potential therapeutic agents for the treatment of disorders associated with inflammatory, thrombotic,

20 ischaemic or neoplastic conditions or prevention of transplant rejection. In particular, the present invention provides a novel model in which endothelial cell activation can be assessed in vivo by a simple and sensitive enzyme assay.

Brief Description of the Drawings

25 Figure 1 (top panel) schematically illustrates the strategy which is pursued in Examples 1 and 2 for targeted replacement of the native mouse E-selectin allele with secreted alkaline phosphatase (SEAP). The SEAP-1 gene, or the SEAP-2 gene fused to the SV40 late mRNA polyadenylation site, is inserted into the mutagenized start site (ATG) of the E-selectin gene, together with a Neo R/loxP fragment. Figure 1 (bottom panel)

schematically depicts the SEAP-1 and SEAP-2 messenger RNAs. In all of the figures, genetic constructs are conventionally depicted with the 5′ terminus at left.

Figure 2(a) ("Endogenous E-selectin locus.") schematically depicts the E-selectin targeting constructs prepared in Examples 1 and 2 for carrying out homologous recombination in murine embryonic stem cells. Said constructs comprise the SEAP-1 gene (or the SEAP-2 gene fused to the SV40 late mRNA polyadenylation site) inserted into the mutagenized start site (ATG) of the E-selectin gene, together with a NeoR gene flanked by loxP sites. Figure 2(b) ("Targeted locus.") depicts the heterologous E-selectin allele (the "targeted locus") (also referred to as the "knock in allele") resulting from integration of the targeted construct into the murine chromosomal E-selectin allele. Figure 2(c) ("Targeted locus after Cre-mediated neo cassette removal.") shows the targeted locus following Cre-mediated removal of the neo casette and one of the LoxP sites.

Figure 3 ("Induction of SEAP by cytokines or LPS") depicts elevated plasma levels of SEAP-1 (left panel) or SEAP-2 (right panel) in TNF- or LPS- induced heterozygous lines, with maximum levels of plama SEAP attained at 6 hours (SEAP-1) or 24 hours (SEAP-2) post-stimulation; and by comparison the absence of induction in NaCl or IFN controls.

Figure 4 ("Analysis of SEAP expression in the two lines") is a bar chart representing pooled data from n experiments which shows elevated plasma levels of SEAP-1- and SEAP-2 (left panel) and fold stimulation (right panel) in transgenic heterozygous (+/-) mice at 6 hours following LPS or TNF induction, compared to baseline levels.

Figure 5 ("Comparison of heterozygous and homozygous animals.") is a bar chart representing pooled data from n experiments which shows elevated plasma levels of SEAP-1 (left panel) and SEAP-2 (right panel) in transgenic homozygous TNF-induced lines relative to transgenic heterozygous lines.

Figure 6 shows the localization of SEAP expression by alkaline phosphatase histochemistry performed on cryosections from tongues of SEAP-2 mice 6 hours after

2

saline ("SEAP-2 control") or LPS injection ("SEAP-2 LPS"). The panels marked "LPS" show the immunolocalization of E-selectin in LPS treated mice. Arrows point to stained vessels.

5   Figure 7 charts the elimination half-life of SEAP in TNF- or LPS- treated SEAP-1 animals in relation to the elimination curve of i.v. administered alkaline phosphatase.

Figure 8 ("Inhibition of SEAP expression by proteasome inhibitor.") illustrates inhibition of SEAP expression in an SEAP-1 line by a proteasome inhibitor, clasto-
10   lactacystine-β-lactone, as compared to placebo, and placebo and TNF.

Detailed Description

The present invention provides in a first aspect a transgenic non-human animal wherein expression of an exogenous soluble marker specifically by endothelial cells, e.g.,
15   vascular endothelial cells, is regulatable by a chemical stimulus, including a cytokine, or a physical stimulus including light or temperature.

In particular, the invention comprises a transgenic non-human animal comprising a polynucleotide encoding a soluble marker protein functionally linked to a regulatory
20   sequence of an endogenous gene encoding E-selectin.

The soluble marker protein is preferably an exogenous protein, i.e. which is not normally produced by the animal. Alternatively, the protein may be produced by the animal but is not normally under the control of a regulatory sequence of an endogenous gene
25   encoding E-selectin. The protein is selected to be detectable in plasma or blood samples by standard experimental means.

Transgenic non-human animals include animals, e.g., mammals, e.g., pigs, cows, goats, as well as non-human primates, such as monkeys, and rodents, such as mice and
30   rats, into which a suitable DNA construct has been introduced directly, as well as progeny of such animals still retaining said construct. Examples for useful animal lines include any animal line normally kept as laboratory animals. This invention shall also be understood to

3

include in all its aspects somatic recombinant non-human animals. The term "transgenic" refers in general to animals having an exogenous gene (i.e. non-native gene, i.e. trans-gene), such as a marker gene, in the chromosomal DNA of their germ line; and the term "somatic recombinant" refers to animals having an exogenous gene, such as for example a

5   marker gene, in the DNA of at least a portion of their somatic cells.

Soluble marker proteins of the invention include proteins with or without enzymatic activity which are conveniently secreted either naturally or as a result of genetic manipulation into the extracellular space. Genes encoding suitable plasma-soluble, non-

10   toxic marker proteins are known (e.g., human growth hormone), commercially available (e.g., a modified, secreted heat stable alkaline phosphatase), or may be prepared following established routes of gene identification, isolation, amplification and modification, e.g., ligation.

15   In preferred embodiments, the soluble marker transgene of the invention is a secreted form of heat-stable human placental alkaline phosphatase gene lacking the membrane anchoring domain, referred to herein as "SEAP"(for "secreted alkaline phosphatase"). Of course, the introduced marker gene need not be limited to the SEAP gene, but may also comprise one or more soluble marker proteins having additional

20   reporter functions.

In its more particular aspects, the invention contemplates a transgenic (or somatic recombinant) non-human animal having inserted in its genome a soluble reporter gene, wherein the soluble reporter gene is under the control of the promoter of an E-selectin

25   gene of a chromosomal E-selectin allele of said animal.

The inserted soluble marker gene can be placed at a variety of positions within the genomic E-selectin sequence, provided that its expression remains under the control of the endogenous E-selectin promoter.

30

The exogenous soluble marker gene is preferably inserted into the genome of the subject animal by means of a "targeting construct" comprising the marker gene under the

4

control of the native E-selectin promoter of the animal to be rendered transgenic or a somatic recombinant, and optional additional transgenes.

Preferably, the targeting construct is also constructed so that the marker gene or
5   other transgene is inserted in a manner to decrease or prevent (i.e. "knock out") expression of the native E-selectin structural gene.

Most preferably, the genetic construct is inserted at the E-selectin allele transcription initiation site, at the E-selectin allele translation initiation site, or at any
10   position in between.

The targeting construct is generally inserted into the host animal genome by homologous recombination into the wild-type chromosomal E-selectin allele, and therefore can be engineered to recombine at any of a variety of positions in the E-selectin allele so
15   long as the inserted marker gene is positioned such that expression of the soluble marker gene is under the control of the E-selectin promoter.

In a preferred embodiment, the E-selectin gene of the non-human animal is modified, as a result of the homologous recombination, by insertion of the genetic
20   construct at a site which is between the transcription and translation initiation sites of the native E-selectin structural gene of the animal, thereby placing expression of the soluble marker gene under the control of the native E-selectin promotor, while "knocking out" normal expression of the E-selectin structural gene.

25   The resulting allele, comprising the inserted soluble marker sequence under the control of the native E-selectin promoter, and optional additional transgenes, is often referred to as a "knock-in" allele.

The invention contemplates a transgenic animal that is either homozygous or
30   heterozygous for the knock-in allele.

5

In its most preferred embodiment, the invention consists of a transgenic mouse that is homozygous or heterozygous for an E-selectin allele having inserted therein a genetic construct comprising a soluble marker gene under the control of the E-selectin promoter, wherein said inserted genetic construct diminishes or prevents expression of the native E-selectin structural gene of that allele. Such a mouse is commonly referred to in the art as a "knock out" mouse.

The targeting construct is preferably constructed so as to assist in homologous recombination of the synthetic sequence with the endogenous gene; and accordingly, will also preferably comprise at least elements of the native structural E-selectin gene.

As indicated above, the targeting construct may comprise additional components such as one or more additional reporters, selection markers such as a neo resistance cassette, and the like. (Upon insertion into the cellular genome of the subject animal, certain selection markers may be excised, for example, by Cre-mediated neo cassette removal.)

Recombinant DNA constructs of the present invention may be prepared according to procedures known in the art, starting from, e.g., a genomic clone. A gene encoding E-selectin and its regulatory sequence may be identified and amplified following procedures known in the art, e.g., by using appropriate primer pairs. Whether one or the other of the methods known in the art for the preparation of the DNA constructs is applied may depend on their intended further use.

The targeting construct of the invention is preferably prepared from an isolated genomic clone of the native E- selectin gene of the subject animal by inserting the marker gene at a suitable position (1) to be under the control of the E-selectin promoter, and (2) to reduce or prevent normal expression of the native structural E-selectin gene.

Preferably, the marker gene itself is inserted between the transcription and translation initiation sites of the isolated genomic E-selectin clone so as to "knock out" normal expression of the endogenous functional E-selectin gene.

6

In a particular embodiment which is illustrated in Example 1, step (a)(v), the targeting construct comprises, in order from 5' to 3': the native murine E-selectin promoter; a fragment of the native murine structural E-selectin gene comprising exon I; an SEAP-encoding component (comprising a Kozak consensus translation initiating signal, the SEAP coding sequence, and an SV-40 late mRNA polyadenylation signal) cloned into the mutated translational start site, Mfe I, of the murine E-selectin gene in exon II; a neoR cassette (comprising a loxP site; a neoR cassette, and a second LoxP site) cloned into intron II; and an additional fragment of the structural E-selectin gene comprising exons III, IV and V. A species of such a targeting construct has SEQ. ID. NO:9.

In another embodiment of a murine SEAP-targeting construct which is illustrated in Example 2, step (a)(ii), the targeting construct comprises, in order from 5' to 3': the native murine E-selectin promoter; a fragment of the native murine structural E-selectin gene comprising exon I; an SEAP-encoding sequence (comprising a Kozak consensus translation initiating signal and an SEAP coding sequence) cloned into the mutated translational start site, Mfe I, of the murine E-selectin gene in exon II, a neoR cassette (comprising a loxP site; a neoR cassette; and a second loxP site) cloned into intron II; and and exons III, IV and V. A species of such a targeting construct has SEQ. ID. NO:10.

Thus this invention provides a recombinant DNA construct comprising a polynucleotide having a nucleotide sequence as illustrated in SEQ ID NO:9 or SEQ ID NO:10.

Well-established methods for germ-line or somatic insertion of a DNA construct include viral or non-viral vector-mediated gene transfer into fertilized eggs, zygotes or early embryos and/or a specific tissue (such as brain) in the adult animal, e.g., by gene transfer into embryonic stem cells, retroviral infection of early embryos or pronuclear microinjection.

For example, gene transfer into embryonic stem cells may be carried out using a "knock-in" strategy performed, e.g., in two sequential steps: (1) by first generating a recombinant DNA construct (the "targeting construct") comprising a genomic clone of the

7

E-selectin gene having inserted therein an exogenous genetic construct comprising the soluble marker gene of interest ; and (2) by transfecting or otherwise inserting the targeting construct into the embryonic stem cells under conditions suitable to effectuate homologous recombination of the targeting construct with the endogenous, chromosomal

5   E-selectin allele.

Identification of successful embryonic stem cell clones may be by, e.g., using the Neo-loxP approach, i.e. by insertion of a Neo resistance cassette carrying the thymidine kinase promoter and Neo cDNA flanked by loxP sites, into an intron of the E-selectin gene.

10   Successfully targeted ES-cell clones may then be transfected with a plasmid expressing the Cre-recombinase, thereby removing the neo-selection cassette (as well as one of the loxP sites in intron II).

Using standard technology for the preparation of a transgenic animal (e.g., a

15   mouse), the insertion of the targeting construct is made in a single allele of the native E-selectin gene, and through genetic crossing, there can thereby be obtained a fertilized egg with the insertion in either a single E-selectin allele, i.e. heterozygous, or in both E-selectin alleles, i.e. homozygous. Further manipulation of resulting fertilized eggs, zygotes or early embryos and breeding of resulting transgenic founder animals follows established routes

20   of breeding transgenic animals. Successful transgenic non-human animals may be identified, e.g., by fur colour, e.g., by the absence of fur colour.

Accordingly, the targeted E-selectin gene ("targeted locus") of Example 1, following Cre-mediated neo cassette removal, is schematically depicted in Figure 2(c) hereof, and

25   comprises, in order from 5' to 3': the native murine E-selectin promoter; a fragment of the native murine structural E-selectin gene comprising exon I; an SEAP-encoding component (comprising a Kozak consensus translation initiating signal, the SEAP coding sequence, and an SV-40 late mRNA polyadenyl-ation signal) cloned into the mutated translational start site, Mfe I, of the murine E-selectin gene in exon II; a single loxP site in intron II, and

30   an additional fragments of the structural E-selectin gene comprising exons III, IV and V. A species of such a targeting construct has SEQ. ID. NO:11.

8

Likewise, the targeted E-selectin gene ("targeted locus") of Example 2, following Cre-mediated neo-cassette removal, is also schematically depicted in Figure 2(c), and comprises, in order from 5' to 3': the native murine E-selectin promoter; a fragment of the native murine structural E-selectin gene comprising exon I; an SEAP-encoding component (comprising a Kozak consensus translation initiating signal and, the SEAP coding sequence) cloned into the mutated translational start site, Mfe I, of the murine E-selectin gene in exon II; a single loxP site in intron II, and an additional fragments of the structural E-selectin gene comprising exons III, IV and V. A species of such a targeting construct has SEQ. ID. NO:12.

Thus this invention also provides a recombinant DNA construct comprising a polynucleotide having SEQ ID NO:11 or SEQ ID NO:12, and a transgenic (or somatic recombinant) non-human animal comprising in its genome a nucleotide sequence having SEQ ID NO:11 or SEQ ID NO:12. Most preferably, the invention consists of a transgenic knockout mouse comprising in its genome SEQ. ID. NO:11 or SEQ. ID. NO;12.

The transgenic or somatic recombinant non-human animals of the invention are useful for readily assessing and non-invasively monitoring in a body fluid, e.g., in plasma, the expression of a marker for E-selectin. An advantage of this model is that the expression of a marker for an inflammatory, thrombotic, ischaemic or neoplastic condition can be followed in an easy and experimentally reproducible system, and time course analyses are possible in this model without killing the animals. For example, this model offers the possibility to assess the specific activation of endothelium in different disease models of e.g., inflammation, angiogenesis, atherosclerosis, thrombosis, and acute or chronic transplant rejection. The model can be used for profiling of compounds inhibiting specific signaling events related to the expression of E-selectin. For example, the model can be used to study the specific effect of inhibitors of the NFκB pathway.

Models based on the transgenic or somatic recombinant non-human animals of the invention may be used for example to identify and assess the efficacy of potential therapeutic agents in disorders associated with inflammatory, thrombotic, ischaemic or neoplastic conditions. In particular such models may be used in screening or

9

Case 31176/A

characterization assays for detecting agents likely to, e.g., prevent or treat inflammation, angiogenesis, thrombosis and acute or chronic transplant rejection.

Accordingly in a further aspect the invention comprises a method for testing a
5   potential therapeutic agent for a specified condition, in particular a disorder associated with inflammatory, thrombotic, ischaemic or neoplastic conditions or transplant rejection, wherein the agent is administered to the transgenic non-human animal. Moreover the invention comprises a screening or characterization assay consisting in or including such a method.

10

Methods for testing potential therapeutic agents using animals are well known in the art. The transgenic non-human animals of the invention may be used in analogous manner.

15   The effects of the potential therapeutic agent may be determined by administering the agent to a transgenic non-human animal, monitoring marker concentration in a body fluid, e.g., plasma, and comparing the result with a result obtained from an untreated transgenic or somatic recombinant non-human animal.

20   In a further embodiment the present invention is directed to a novel modulator of a regulatable protein identified by a screening assay comprising administering the potential modulator to a transgenic or somatic recombinant non-human animal, monitoring marker concentration in a body fluid, e.g., plasma, and comparing the result with a result obtained from an untreated such animal.

25

Methods for monitoring marker concentration in a body fluid are well known in the art. For example, concentration of a marker enzyme may be determined by quantifying the enzymatic activity. Marker proteins without enzymatic activity may be quantified by other means e.g., by immunological methods.

30

The transgenic non-human animals are further useful to monitor disease development and progression in established models of disease involving spontanously

10

developing or induced disease conditions in wild-type or transgenic animals. For this, the transgenic non-human animals may be crossed with animal strains known for their use as animal models. Examples for suitable animal strains include mouse strains, e.g., atherosclerosis prone mice, e.g., targeted disruption of e.g., LDL-R or Apo E; mouse models for inflammation, e.g., mouse strains showing defects in NFκB signalling, defects in TNF and TNF-R, IL-1 and IL-1-R, or mutations such as the MRL-lpr mouse; mouse strains with immune disorders, e.g., cytokine transgenic or knockout mice; Thrombosis-prone mice, e.g., plasminogen or plasminogen activator deficient mice; and mouse strains which develop tumors. Disease progression may be monitored by e.g., following marker gene expression in the F1 animals or in offsprings resulting from crossing in of the transgenic non-human animals for several generations into the respective disease model strain.

The transgenic animals of the invention can also be used to study tissue distribution of E-selectin expression by various analytical methods including in situ histological analysis of the expression pattern of the reporter gene, and in vitro detection of the reporter gene in various tissues, tissue sections and/or cell types.

The invention further contemplates isolated cells or a cell culture derived from a transgenic animal (e.g., mouse) of the invention. The cells can be obtained directly from the animal, from a descendent animal, or can be a progeny of a primary culture of one or more cells of the animal. The isolated cell can be in the form of a single cell or cell line, or a composition of mixed cells. The cell can be obtained from an animal which is the descendant of a transgenic animal of this invention, such as by a cross with another animal having either the same or a different genetic background. Thus an isolated cell can be either homozygous or heterozygous for a reporter gene in the E-selectin allele. The isolated cell is preferably an endothelial cell.

In accordance with the foregoing the present invention thus provides

(1) A transgenic or somatic recombinant non-human animal, e.g., a mammal, e.g., a pig, a primate, such as a monkey, or a rodent, such as a mouse or a rat, wherein expression of an exogenous soluble marker, e.g., human growth hormone or a modified,

11

secreted heat stable alkaline phosphatase, specifically by endothelial cells, e.g., vascular endothelial cells, is regulatable by a chemical stimulus, including a cytokine, or a physical stimulus including light or temperature, e.g., a transgenic non-human animal comprising a polynucleotide encoding a soluble marker protein functionally linked to a regulatory

5   sequence of an endogenous gene encoding E-selectin; and isolated cells of said animal.

(2) A transgenic non-human animal wherein in the presence of a stimulus, e.g., an inflammatory cytokine, a soluble marker is specifically produced by endothelial cells.

(3) A transgenic non-human animal comprising a recombinant DNA construct comprising a polynucleotide having a nucleotide sequence as illustrated in SEQ ID NO:11

10   or SEQ ID NO:12.

(4) A non-human animal being an offspring of a transgenic non-human animal as under (1), (2) or (3) crossed with a non-human animal showing a disease condition and/or its sequellae, e.g., symptoms, resulting from an altered genetic background, either spontaneously developed or following genetic manipulation.

15   (5) A transgenic non-human animal cell comprising a recombinant DNA construct comprising a polynucleotide having a nucleotide sequence as illustrated in SEQ ID NO:11 or SEQ ID NO:12.

(6) A recombinant DNA construct comprising a polynucleotide having a nucleotide sequence as illustrated in SEQ ID NO:9 or SEQ ID NO:10.

20   (7) A method for testing a potential therapeutic agent for a specified condition, in particular a disorder associated with inflammatory, thrombotic, ischaemic or neoplastic conditions or transplant rejection, wherein the agent is administered to a transgenic non-human animal as under (1), (2) or (3), monitoring marker concentration in a body fluid, e.g., plasma, and comparing the result with the result obtained from an untreated

25   transgenic or somatic recombinant non-human animal as under (1), (2) or (3), an elevated level being indicative of the potential of the agent.

(8) A method for screening of modulators of E-selectin expression comprising the steps of

(a) administering the potential modulator to a transgenic or somatic recombinant

30   non-human animal as under (1), (2) or (3),

(b) monitoring marker concentration in a body fluid, e.g., plasma, and

12

(c) comparing the result with the result obtained from an untreated transgenic or somatic recombinant non-human animal as under (1), (2) or (3), a modulated level being indicative of the therapeutic potential of the agent.

(9) A novel modulator of E-selectin expression identified by a method as under (6) or (7).

(10) A method for treating a patient suffering from an inflammatory, thrombotic, ischaemic or neoplastic condition or from transplant rejection comprising administering to the patient a pharmaceutically effective amount of a modulator as under (8).

(11) A method to monitor disease development and progression in established models of disease involving spontanously developing or induced disease conditions in wild-type or transgenic animals comprising

(a) crossing of the transgenic non-human animals as under (1), (2) or (3) with animal strains known for their use as animal models and

(b) monitoring disease progression in offsprings in relation to marker concentration in a body fluid.

The following examples illustrate the invention without limitation.

Example 1   Preparation of transgenic mice expressing a secreted heat stable alkaline phosphatase gene under the control of the E-selectin regulatory sequence without the 3'UTR of E-selectin containing the mRNA destabilizing AUUUA repeats

(a) Preparation of DNA construct

(i) Mutation of the ATG start codon

The ATG start site of E-selectin is mutated from ...GTC ATG AAT... to ... GTC AAT TG AAT... to introduce a unique Mfe I restriction site (underlined) within the genomic E-selectin fragment for cloning of SEAP, as follows:

A ~6kb XbaI genomic mouse E-selectin clone (D3-ES cells) in the pBS-KS(-) vector (Stratagene) is used to modify the ATG start codon by PCR. The 5'-fragment is amplified by PCR using the primerpair SEQ ID NO:1 and SEQ ID NO:2 [50 µl standard reactions are

13

prepared using 400 nM primer, 200 nM dNTP's, PCR buffer with 1.5 mM MgCl$_2$, 1.5 U Taq DNA polymerase in a PTC-200 thermocycler]. The 3'-fragment is amplified with the primerpair SEQ ID NO:3 and SEQ ID NO:4. The two fragments are purified using agarose gel electrophoresis. 200 fmol of each partial fragment is used for a PCR pre-amplification

5 without primers to generate the full-length fragment (4x 94° 60"; 40° 120"; 72° 120"). The full-length fragment is amplified using primers SEQ ID NO:1 and SEQ ID NO:2 in a standard PCR reaction. The PCR fragment is gel purified, digested with Afl-2, the DNA precipitated using sodium acetate/ethanol, cut with BamH1 and purified by agarose electrophoresis.

10

(ii) mE-selectin with mutated ATG (mE-Sel/mutATG).

Genomic XbaI/mE-Sel/pBS-KS(-) clone (is partially cut with BamH1, the 8.5kb fragment isolated using gel electrophoresis and digested with Afl-2. The 8 kb fragment is purified and ligated with the 520 bp PCR fragment obtained in (i) above carrying the

15 mutated ATG start codon. The ligation mixture is precipitated (sodium acetate/ethanol) and redissolved in TE Buffer pH 8.0. 2 μl (20%) of the ligation is electroporated into E.coli XL1-blue electrocompetent cells and clones screened by PCR followed by precipitation and digestion. Several positive clones are verified by sequencing using standard protocol.

20 ### (iii) mE-selectin with mutated ATG/Neo cassette (mE-Sel/mutATG/Neo).

2.3 μg plasmid mE-Sel/mutATG is linearised with Afl-2 and blunt ended with Klenow DNA polymerase using standard protocol and the gel purified vector is dephosphorylated with Shrimp alkaline phosphatase (SAP). The Neo cassette is isolated by digesting 5 μg plasmid pRay-2 [Storck et al., Nucleic Acids Res. 24:4594-4596 (1996)]

25 with Xho-1, the DNA precipitated cut with Xma-1. The 1400 bp NeoloxP fragment is purified by gel electrophoresis and 0.5 μg of the isolated fragment is blunt ended using Klenow. 7 fmol Vector and 20 fmol NeoloxP fragment are ligated und electroporated into E.coli XL1-blue, clones selected by PCR (SEQ ID NO:1 and SEQ ID NO:2). Several isolated plasmids are controlled by restriction digest (Sph1, Xba1, Nco1, BamH1) and for a

30 3'-5' orientation of the NeoloxP insert.

(iv) mE-Selectin with SEAP-2 in mutated ATG site (mE-Sel/SEAP-2/Neo).

Case 31176/A

5 µg plasmid mE-Sel/mutATG/Neo is linearized with Mfe-1, purified by gel electrophoresis and the isolated vector dephosphorylated with SAP. The SEAP-2 fragment is isolated from 5 µg plasmid "pSEAP2"(Accession No: U09660; Clontech) by EcoR1 and Mfe-1 digestion. The 1703 bp fragment is purified using gel electrophoresis. 5 fmol vector and 20 fmol SEAP-2 are ligated and electroporated into *E.coli* XL1-blue as described above. Clones are selected by plasmid digestion using Nde-1; BamH1; Xba-1 and the sequence of several positive clones is verified by DNA sequencing. Figure 1 schematically depicts the insertion of the SEAP-2 fragment into linearized mE-Sel/mutATG/Neo.

v) Generation of targeting construct SEQ ID NO:9.

6.6 µg plasmid mE-Sel/SEAP-2/Neo is linearized with Bpu10I and the 6370bp fragment isolated by gel electrophoresis and blunt ended with Klenow. 2 µg plasmid pBS2-SK(-) (Stratagene) is linearised with EcoRV, purified and dephosphorylated with SAP. 30 fmol Bpu10I fragment are ligated with 15 fmol vector pBS2SK and electroporated into *E.coli* XL1-blue. Clones are selected by Xba-1, BamH1, and EcoR1 digestion. 120 µg endotoxin-free plasmid Tar-mE-Sel SEAP-2/Neo is linearised with Not-1, heat inactivated, precipitated and redissolved in 70 µl TE Buffer low EDTA (0.1mmolar). The resulting targeting construct is a polynucleotide having SEQ. ID. NO:9. Figure 2(a) depicts the SEAP-2 targeting construct and its insertion site in the endogenous E-selectin locus.

(b) Generation of E-selectin-SEAP knock-in BALB/c ES cell lines.

5×10^6 BALB/c ES cells [Noben-Trauth et al.,Transgenic Res. 5:487-491 (1996)] are electroporated with 30 µg of the linearized targeting construct. Transfected cells are selected with G418 (200 µg/ml). Figure 2(b) schematically depicts the targeting construct as inserted into the targeted locus of the endogenous E-selectin gene. G418-resistant clones are screened for homologous recombination events by PCR [the ES cells are lysed 1h/37° with 20 µl Lysis buffer (PCR buffer 1X; SDS 1.7 µM; Proteinase K 50 µg/ml) heat inactivated 85°/15 Min. and cleared by centrifugation. 1,3 µl lysed solution is used in for a 50 µl nested PCR. PCR (1): primer pair SEQ ID NO:5 and SEQ ID NO:6 (20 cycles)

15

followed by PCR (2): 1.3ul PCR (1) and primer pair SEQ ID NO:7 and SEQ ID NO:8 using 25 cycles.] and positive clones are further verified by Southern analysis.

Targeted ES lines are subjected to a further electroporation with a plasmid carrying the Cre gene under the transcriptional control of the HSV tk-promoter. Individual clones are grown in duplicate 96-well plates in the presence or absence of G418. The targeted locus after Cre-mediated neo cassette removal (leaving one loxP locus) is depicted in Figure 2(c). The absence of the neo selection cassette is verified by Southern blot analysis of individual G418 sensitive clones.

(c) Generation of E-selectin-SEAP knock-in mice

BALB/c-ES cell clones carrying one E-selectin-SEAP allele are injected into BL/6-III host blastocysts and transferred into pseudopregnant foster mothers according to standard protocols. Chimeras are mated with BALB/c females and albino offspring (indicative for germ line transmission) are analyzed by PCR for target integration [200 ng genomic DNA are used in the same nested PCR as described in (vi) but in 30 µl reactions] and Southern analysis. Heterozygous animals are generated by back-crossing of F1 animals to Balb/c wild type animals and Southern analysis of the F2 animals. The homozygous lines are established by mating heterozygous F1 animals.

Example 2   Preparation of transgenic mice expressing a secreted heat stable alkaline phosphatase gene under the control of an E-selectin regulatory sequence maintaining the 3'UTR of E-selectin containing the mRNA destabilizing AUUUA repeats

(a) Preparation of DNA construct.

(i) mE-Selectin with SEAP-1 in mutated ATG site (mE-Sel/SEAP-1/Neo).

5 µg plasmid obtained in Example 1(a)(ii) is cut with EcoR1 and Bsm-1 and the 1615 bp fragment purified by gel electrophoresis. 45 fmol SEAP-1 fragment is ligated into 5 fmol mE-Sel/mutATG/Neo, linearized with Mfe-1 and dephosphorylated, using 22 fmol Linker Bsm-1/Mfe-1 (GTTTAA). Figure 1 schematically depicts the insertion of the SEAP-

16

1 fragment into linearized mE-Sel/mutATG/Neo. Clone selection and sequencing are done as described above. The selected clone has a deletion of two base pairs (CA) in the Bsm1 site located 40 bp 3' of the Stop codon.

5   (ii) <u>Generation of Targeting construct SEQ ID NO:10.</u>

5 µg plasmid mE-Sel/SEAP-1/Neo are treated as described above. 120 µg endotoxin-free plasmid Tar-mE-Sel SEAP-1/Neo is linearised with Not-1, heat inactivated, precipitated and redissolved in TE buffer (0.1 mM EDTA). The resulting targeting construct is a polynucleotide having SEQ. ID. NO:10. Figure 2(a) depicts the SEAP-1 targeting

10 construct and its insertion site in the endogenous E-selectin locus.

(b) <u>Generation of E-selectin-SEAP knock-in BALB/c ES cell lines and mice.</u>

Cell lines and mice are generated following the protocol as described in Example 1 (b) and (c) above.

15

<u>Test 1: LPS and cytokine induction of SEAP expression in heterozygous mice.</u>

Heterozygous mice of Example 1 and Example 2 are injected with LPS (Sigma, Serotype 0:111B4 Cat. L4130) at a dose of 25 µg per mouse. Murine recombinant TNFα (R&D Systems, Cat No. 410-MT) is diluted in sterile saline and administered at a dose of

20 500 ng/mouse. Administration is intravenously, <u>e.g.,</u> into the tail vein, subcutaneously or intraperitoneally.

Blood for analysis is taken from a superficial vein of the mouse into heparinized glass hematocrit capillaries. The blood is centrifuged in a table-top Eppendorff centrifuge

25 at maximal speed for 5 min to prepare plasma.

A standard curve is created with human placental alkaline phosphatase (PAP) (Sigma Cat. P-3895). A stock solution of 2 mg/ml dissolved in buffer (Tris/HCl 50 mM pH 7.4; NaCl 150 mM; BSA 1 %) is stored at -80°C in aliquots. The standard curve is diluted in

30 mouse plasma containing Heparin. The range of the standard curve is between 0.5 and 50000 ng/mL PAP.

17

For the enzyme assay the Tropix Kit (Tropix, Cat. No BP300) is used. The analysis of heat stable alkaline phosphatase activity in standards and samples is performed in duplicates according to the manufacturer's suggestion.

5   The results are plotted in Figures 3 and 4. Figure 3 shows that animals of Example 1 and Example 2 display significantly increased levels of circulating SEAP 6 hours after the administration of LPS as well as TNFα. The maximal levels of plasma SEAP are reached at 6 hours post-stimulation in animals of Example 2, the maximum reached in animals of Example 1 is not seen until 24 hours post stimulation. SEAP-2 mice express about 1000-

10   fold more marker enzyme than SEAourP-1 animals. NaCl and IFNg (which are known not to induce E-selectin *in vitro*) have no effect on SEAP induction in either line, demonstrating that SEAP expression follows the same stimulation pattern as E-selectin. Figure 4 shows pooled data obtained at the 6 hour time point from n experiments. The plasma levels and the stimulation factors are shown (means +/- SEM). In the SEAP-1 line, LPS-or TNF-

15   stimulated SEAP expression at 6 hours is higher than in the SEAP-2 line (about 10-fold vs. about 3-fold).

Test 2: LPS and cytokine induction of SEAP expression in homozygous mice.

The baseline plasma levels of SEAP is consistently and significantly higher in the

20   homozygous compared to the heterozygous animals. The level of expression 6 hours after TNFα challenge is about 3-fold higher in the homozygous mice compared to the heterozygous animals of Example 1 and Example 2 while no change is seen in either line in saline-injected control animals. Figure 5 depicts a comparison of blood samples taken from heterozygous and homozygous mice treated with murine TNFa (500 ng/mouse) at 6

25   hours after stimulation (means +/- SEM of n animals per group).

Test 3: Analysis of the site of SEAP expression.

Animals from Example 1 and Example 2 are treated with either LPS or saline, killed after 6 hours and organs removed for histology. Wild-type animals serve as controls.

30

After fixation for 3 hours in 4 % PBS-buffered paraformaldehyde, tissues are infused with sucrose over night, embedded in OCT compound and snap frozen. The

18

following results are obtained with tongue tissue. Cryosections (8 μm) are taken on polylysine coated slides, briefly dried and then stored at -80°C. For enzyme histochemistry, slides are brought to room temperature and then incubated for 45 min at 65°C in 50 mM Tris/100 mM NaCl. The sections are cooled to room temperature and further incubated in

5   alkaline phosphatase substrate mixture prepared as follows: 100 mg nitro tetrazolium blue and 30 mg 5-bromo-4-chloro-3-indolyl phosphate are each dissolved in 5 ml N,N-dimethylformamide and then added to 90 ml 200 mM Tris buffer pH 9.2. The sections are incubated at 37°C for 3-4 h, briefly washed, counter-stained and inspected under a microscope. Immunohistochemistry is performed with anti CD31 and anti E-selectin

10   antibody.

    In the non-heat inactivated tissue sections from mouse tongue very strong alkaline phosphatase activity is observed in several cell types. In the sections which were heat-inactivated, the background alkaline phosphatase activity is absent in the wild type control

15   animals as well as in the SEAP-1 animals of Example 2 and, as shown in Figure 6, in the unstimulated SEAP-2 animal of Example 1 (boxes marked "SEAP-2 control"). In the LPS-treated animal of Example 1 (Figure 6, boxes marked "SEAP-2 LPS") a specific staining is seen in the endothelium of some but not all vessels. The stained vessels are the same as those which express E-selectin after LPS stimulation (se Figure 6, boxes marked "LPS").

20   Thus heat stable alkaline phosphatase enzyme activity is detected upon LPS stimulation in SEAP-2 mice in the same vessels as those which in wild type animals express E-selectin.

    Test 4: Elimination Kinetics of SEAP. The elimination kinetics of SEAP are investigated in an experiment in which wild-type mice are injected i.v. with human alkaline

25   phosphatase, and plasma samples are analyzed. A conventional PK method is employed to analyze plasma concentration data and to estimate amount of SEAP expressed after stimulation, yielding the following data:

19

Animal Group	Parameters	TNF		LPS	
		mean	SD	mean	SD
SeAP-1	AUC (ng·h/mL)	3250	1040	3990	660
	Expression (ng)	321	102	393	65
SeAP-2	AUC (ng·h/mL)	2740	700	3930	160
	Expression (? g)	270	69	388	16

Endogenously produced SEAP is found to distribute mainly into the blood stream. As depicted in Figure 7, the elimination half-life of SEAP is about 10 hours.

5

Test 5: Effect of inhibitory compounds on SEAP expression.

. Clasto-lactacystine-β-lactone, a commercially available proteasome inhibitor is dissolved in DMSO (10 μl/100μg) and further diluted with 90 μl Peg300. This mixture is further diluted 1:10 in saline and injected i.v. to animals of Example 2 at a dose of 1 mg/kg.

10   Ten to 15 min later TNF is administered i.p. to compound-treated or untreated animals of Example 2. Blood samples are taken from the animals at baseline, 6 hours and 24 hours and SEAP levels analyzed. A significant inhibition of marker enzyme expression is observed 6 hours after TNF administration in the animals which received clasto-lactacystine-β-lactone and TNF compared to the animals which received TNF alone

15   ($p=0.045$, two-way ANOVA). Figure 8 shows that in SEAP-1 animals, the proteasome inhibitor significantly inhibits marker enzyme expression after TNF stimulation at 6 hours, but shows no effect at 24 hours in this mouse line. In SEAP-2 animals the compound does not modify SEAP expression at 6 hours or 24 hours after TNF simulation

20   ### Test 6:   Time course of endothelial activation during atherosclerotic lesion development.

Homozygous mice derived from animals from Example 1 or Example 2 are mated to homozygous mouse strains prone to atherosclerosis, e.g., LDL-R -/- or apoE -/-. The offspring of these animals are fed a high cholesterol diet. At weekly intervals blood

25   samples are taken and marker enzyme is quantified. Mice show an increase in marker enzyme prior to fatty lesion development.

20 ·

<u>Test 7: Endothelial cell activation during progression of inflammatory disease.</u>

Animals from Example 1 or Example 2 are crossed with mouse strains predisposed to spontaneous development of inflammatory disorders <u>e.g.,</u> the MRL-lpr mouse strain.

5 Blood samples are taken from offspring at daily-to weekly time intervals and marker enzyme expression is monitored. The level of marker enzyme expression is correlated with disease onset.

21

<110> Novartis AG

5   <120> Transgenic animals for studying regulation of genes

<130> SEAP mice

<140>
10 <141>

<160> 12

<170> PatentIn Ver. 2.1
15

<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence
20

<220>
<223> Description of Artificial Sequence:primer

<400> 1
25 gcagtgctca gtggtcctcg a   21

<210> 2
<211> 27
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

22

<400> 2

tcaattgact ccagcagttg ctttcat   27

<210> 3

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 3

gaaagcaact gctggagtca attgaatgcc tcgcgctttc tc   42

<210> 4

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 4

gctaatcacc atataacgca c   21

<210> 5

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

23

<400> 5
cctttccaac ttgcttcctt tatctgag   28

<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 6
agtttgtcct tcttctgccc ttttag   26

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 7
cctctcccccg tggcatcc   18

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

24

<220>

<223> Description of Artificial Sequence:primer

<400> 8

aagtccgggt tctcctcctc aa   22

<210> 9
<211> 6408
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:targeting
      sequence

<400> 9

cgataagctt gatttagcat ataatcagcg gtctaggtca ctaagtaggt actgtgtcac 60
tacagatacc atattaccac tgttgaaacg agaaatctag tatgaataga acatgagaag 120
aaacattcag gaatgactcc cctgcaccccc agtgcctgtt aggatggcct aaggtagcag 180
tgactgagca gaaccttggc actgatgtac gtatcatcaa cagttatcca caagaaaatc 240
gagagtgaca gatcatgggt aataaaatac tcttagtttg ctcatctttg tgaaaccaag 300
ttctacactt gattgataat ggtaattaga ctttataaca caagacttaa catcacacac 360
ttgtatccca tttgataaaa ctgcatacaa atataagagc ccagaaaaag aattaattta 420
gaggggcaga gtctctgaca tcactatgaa agtgttttaa ctcagtggat attcccagaa 480
aactttttgg atgcagttga gaatttcctc ttagccagat tttgataata atgtcctatg 540
actcacagga agccagctcc cctataaaga ggctccagca gaagcagtgc tcagtggtcc 600
tcgactgact acacagcaaa actgcgagaa gaacggatag agagaagcag gagcaataca 660
cctaagggat ccaacgccag aacaacaatt ccactgaaca gtaagtgcgg attccgaacc 720
agaggagcct tgggcccgaa gcatagattt atgtgtgctc acatacgcaa aaaaaaaaa 780
aaaaagtcat tctgattaaa aaagacctgt ctaaactgtt atagtgttgt aattaatacc 840
tacattttct ctttgtttaa aatgatggaa atcttaaagt ctgcatttat tctccatgct 900
agatgcctgt gaaataaggg atgaggtaca ggattctaaa acctcacagc tttgacttaa 960
atgctgttgt agaaggatgt gagtaacccg cacttagaat ttccttctgt gactaattct 1020
gcactttctc tcctcaggaa agtttctcca gtctagcgcc tggatgaaag caactgctgg 1080

25

Case 31176/A

```
agtcaattcg cccaccatgc tgctgctgct gctgctgctg ggcctgaggc tacagctctc 1140

cctgggcatc atcccagttg aggaggagaa cccggacttc tggaaccgcg aggcagccga 1200

ggccctgggt gccgccaaga agctgcagcc tgcacagaca gccgccaaga acctcatcat 1260

cttcctgggc gatgggatgg gggtgtctac ggtgacagct gccaggatcc taaaagggca 1320

gaagaaggac aaactggggc ctgagatacc cctggccatg accgcttcc catatgtggc 1380

tctgtccaag acatacaatg tagacaaaca tgtgccagac agtggagcca cagccacggc 1440

ctacctgtgc ggggtcaagg gcaacttcca gaccattggc ttgagtgcag ccgcccgctt 1500

taaccagtgc aacacgacac gcggcaacga ggtcatctcc gtgatgaatc gggccaagaa 1560

agcagggaag tcagtgggag tggtaaccac cacacgagtg cagcacgcct cgccagccgg 1620

cacctacgcc cacacggtga accgcaactg gtactcggac gccgacgtgc ctgcctcggc 1680

ccgccaggag gggtgccagg acatcgctac gcagctcatc tccaacatgg acattgacgt 1740

gatcctaggt ggaggccgaa agtacatgtt tcgcatggga accccagacc ctgagtaccc 1800

agatgactac agccaaggtg ggaccaggct ggacgggaag aatctggtgc aggaatggct 1860

ggcgaagcgc cagggtgccc ggtatgtgtg gaaccgcact gagctcatgc aggcttccct 1920

ggacccgtct gtgacccatc tcatgggtct ctttgagcct ggagacatga aatacgagat 1980

ccaccgagac tccacactgg acccctccct gatggagatg acagaggctg ccctgcgcct 2040

gctgagcagg aaccccgcg gcttcttcct cttcgtggag ggtggtcgca tcgaccatgg 2100

tcatcatgaa agcagggctt accgggcact gactgagacg atcatgttcg acgacgccat 2160

tgagagggcg ggccagctca ccagcgagga ggacacgctg agcctcgtca ctgccgacca 2220

ctcccacgtc ttctccttcg gaggctaccc cctgcgaggg agctccatct tcgggctggc 2280

ccctggcaag gcccgggaca ggaaggccta cacggtcctc ctatacggaa acggtccagg 2340

ctatgtgctc aaggacggcg cccggccgga tgttaccgag agcgagagcg ggagccccga 2400

gtatcggcag cagtcagcag tgcccctgga cgaagagacc cacgcaggcg aggacgtggc 2460

ggtgttcgcg cgcggccgc aggcgcacct ggttcacggc gtgcaggagc agaccttcat 2520

agcgcacgtc atggccttcg ccgcctgcct ggagccctac accgcctgcg acctggcgcc 2580

ccccgccggc accaccgacg ccgcgcaccc gggttactct agagtcgggg cggccggccg 2640

cttcgagcag acatgataag atacattgat gagtttggac aaaccacaac tagaatgcag 2700

tgaaaaaaat gctttatttg tgaaatttgt gatgctattg ctttatttgt aaccattata 2760

agctgcaata aacaagttaa caacaacaat tgaatgcctc gcgctttctc tctgctcttg 2820

tttttggtaa gctggagtca cgggagacca gggactctca ccctcacccc agtgactctt 2880

aaccggggta ctcgacctgc agccaagcta gcttggctgg acgtaaactc ctcttcagac 2940

ctaataactt cgtatagcat acattatacg aagttatatt aagggttatt gaatatgatc 3000

ggaattcctc gacggatccg aacaaacgac ccaacacccg tgcgttttat tctgtctttt 3060

tattgccgat cccctcagaa gaactcgtca agaaggcgat agaaggcgat gcgctgcgaa 3120
```

```
tcgggagcgg cgataccgta aagcacgagg aagcggtcag cccattcgcc gccaagctct 3180

tcagcaatat cacgggtagc caacgctatg tcctgatagc ggtccgccac acccagccgg 3240

ccacagtcga tgaatccaga aaagcggcca ttttccacca tgatattcgg caagcaggca 3300

tcgccatggg tcacgacgag atcctcgccg tcgggcatgc gcgccttgag cctggcgaac 3360

agttcggctg gcgcgagccc ctgatgctct tcgtccagat catcctgatc gacaagaccg 3420

gcttccatcc gagtacgtgc tcgctcgatg cgatgtttcg cttggtggtc gaatgggcag 3480

gtagccggat caagcgtatg cagccgccgc attgcatcag ccatgatgga tactttctcg 3540

gcaggagcaa ggtgagatga caggagatcc tgccccggca cttcgcccaa tagcagccag 3600

tcccttcccg cttcagtgac aacgtcgagc acagctgcgc aaggaacgcc cgtcgtggcc 3660

agccacgata gccgcgctgc ctcgtcctgc agttcattca gggcaccgga caggtcggtc 3720

ttgacaaaaa gaaccgggcg cccctgcgct gacagccgga acacggcggc atcagagcag 3780

ccgattgtct gttgtgccca gtcatagccg aatagcctct ccacccaagc ggccggagaa 3840

cctgcgtgca atccatcttg ttcaatggcc gatcccatgg taaaaaccct cctcgcaggg 3900

tcgctcggtg ttcgaggcca cacgcgtcac cttaatatgc gaagtggacc tgggaccgcg 3960

ccgccccgac tgcatctgcg tgttcgaatt cgccaatgac aagacgctgg gcggggtttg 4020

ctcgacattg ggtggaaaca ttccaggcct gggtggagag gctttttgct tcctcttgca 4080

aaaccacact gctcgacatt gggtggaaac attccaggcc tgggtggaga ggctttttgc 4140

ttcctcttga aaaccacact gctcgacctg cagccaagct agcttggctg gacgtaaact 4200

cctcttcaga cctaataact tcgtatagca tacattatac gaagttatat taagggttat 4260

tgaatatgat cggaattcct cgattaagag caggatattt tgttgtgtgg ggctttctgt 4320

gcgttatatg gtgattagca gaactgatga cctccctgca gggttctgcc ttgtggtggg 4380

aagggtggat tttaagtgct ttgtgaagag tcgttcatct ggctcctgaa aggggctca 4440

aacaggcacc acgtagcatc caatgaagtt tgctttctct gacttccatt gtactgtgag 4500

gttggaatat aacattgcgg ttgccataag gcaccaccag ataatggcac acggtgatat 4560

atagaaattc tagccccttg agatgatcct cttcttactt ttaaaatcaa tagtttgaac 4620

caacaaaagg accctataaa ccaaaagcaa gacaacacga ttcaggacta aactttgcta 4680

tctctttctt gacccaatcc agttctcctc gctggagaga gcacagcttg gtactacaat 4740

gcctccagtg agctcatgac gtatgatgaa gccagtgcat actgtcagcg ggactacaca 4800

catctggtgg caattcagaa caaggaagag atcaactacc ttaactccaa tctgaaacat 4860

tcaccgagtt actactggat tggaatcaga aaagtcaata cgtatggat ctgggtgggg 4920

acggggaagc ctctgacaga ggaagctcag aactgggctc caggtgaacc aaacaacaaa 4980

caaagaaatg aggactgtgt agagatttac atccaacgaa ccaaagactc gggcatgtgg 5040

aatgacgaga gatgtaacaa aaagaagctg gctctgtgct acacaggtat gaagtttctg 5100

catggtggaa ggctggctct gtgtggaggc agcctgacag attgagagtt gtataaagga 5160
```

27

```
    attggtctct actagttttt tcaaagagat gattataagt gattttaata gtaattgcat 5220

    ctcttagtac tgatttgtgt gagtagaggc aagatatata catatatgtg tgtgtgtatg 5280

    tatgtactta tatgtataca tataataatt ctatcaatat acagagtata tatatttgca 5340

    taaaaataaa atatgtggtt tagttgtagc tattctgatg tgtatttatt accaccaaaa 5400

5   tatacaacag atgagactgg aacttgtatc tggcatgcca atcaaaatct ccagcactaa 5460

    tgtcattaga gtcatctgga ttgcactgat tctaaattac aaacaaacaa actcatgatg 5520

    agcaccatac taattgactg tcctcatatg gactgtgttt tctgtagctt cgtgtaccaa 5580

    tgcatcctgc agtggtcatg gtgaatgcat agagaccatc aatagttaca cctgcaagtg 5640

    ccaccctggc ttcctgggac ccaactgtga gcaaggtaag tcttgtcctc acctgtttct 5700

10  tctccaagat ggtaacaccc tctcctcccc cagatggctt gtgatggctt gtcagtcggg 5760

    cccatgtgtt tcctctactg agtaagagtg atatagtggc tgagactatg agatcagatc 5820

    ctcctgggtc aaactgcaga cctactaccc gtattactta tggcaccttg acaaagtagt 5880

    cctgtagggt gactgacgat tccagttgtc atgaaactaa ataacatcat gtggcaatta 5940

    gctgaagctt agcgttttag ttccagagaa cgacaaagaa actgtttcat agtctgatgg 6000

15  ttccatagag cctggaccac aggaaatgtt caatgggtga taattatggt gaccagcgtt 6060

    cctctctcag atgcaaaggg agagatgagc agacgtgtgt cttgattcgt tgttttgttt 6120

    gattttcag ctgtgacttg caaaccacag gaacaccctg actatggaag cctgaactgc 6180

    tcccacccgt tcggcccctt cagctataat tcctcctgct cctttggctg taaaaggggc 6240

    tacctgccca gcagcatgga gaccaccgtg cggtgtacgt cctctggaga gtggagtgcg 6300

20  cctgctccag cctgccatgg taactctccc aatgcagtaa acctcttcac tcctcctcat 6360

    tgccttaatc gaattcctgc agcccggggg atccactagt tctagagc         6408
```

<210> 10

<211> 6314

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:targeting
    sequence

<400> 10

cgataagctt gatttagcat ataatcagcg gtctaggtca ctaagtaggt actgtgtcac 60

```
        tacagatacc atattaccac tgttgaaacg agaaatctag tatgaataga acatgagaag  120

        aaacattcag gaatgactcc cctgcacccc agtgcctgtt aggatggcct aaggtagcag  180

        tgactgagca gaaccttggc actgatgtac gtatcatcaa cagttatcca caagaaaatc  240

        gagagtgaca gatcatgggt aataaaatac tcttagtttg ctcatctttg tgaaaccaag  300

 5      ttctacactt gattgataat ggtaattaga ctttataaca caagacttaa catcacacac  360

        ttgtatccca tttgataaaa ctgcatacaa atataagagc ccagaaaaag aattaattta  420

        gaggggcaga gtctctgaca tcactatgaa agtgttttaa ctcagtggat attcccagaa  480

        aactttttgg atgcagttga gaatttcctc ttagccagat tttgataata atgtcctatg  540

        actcacagga agccagctcc cctataaaga ggctccagca gaagcagtgc tcagtggtcc  600

10      tcgactgact acacagcaaa actgcgagaa gaacggatag agagaagcag gagcaataca  660

        cctaagggat ccaacgccag aacaacaatt ccactgaaca gtaagtgcgg attccgaacc  720

        agaggagcct tgggcccgaa gcatagattt atgtgtgctc acatacgcaa aaaaaaaaa  780

        aaaaagtcat tctgattaaa aaagacctgt ctaaactgtt atagtgttgt aattaatacc  840

        tacattttct ctttgtttaa aatgatggaa atcttaaagt ctgcatttat tctccatgct  900

15      agatgcctgt gaaataaggg atgaggtaca ggattctaaa acctcacagc tttgacttaa  960

        atgctgttgt agaaggatgt gagtaacccg cacttagaat ttccttctgt gactaattct  1020

        gcactttctc tcctcaggaa agtttctcca gtctagcgcc tggatgaaag caactgctgg  1080

        agtcaattcg cccaccatgc tgctgctgct gctgctgctg ggcctgaggc tacagctctc  1140

        cctgggcatc atcccagttg aggaggagaa cccggacttc tggaaccgcg aggcagccga  1200

20      ggccctgggt gccgccaaga gctgcagcc tgcacagaca gccgccaaga acctcatcat  1260

        cttcctgggc gatgggatgg gggtgtctac ggtgacagct gccaggatcc taaaagggca  1320

        gaagaaggac aaactggggc ctgagatacc cctggccatg gaccgcttcc catatgtggc  1380

        tctgtccaag acatacaatg tagacaaaca tgtgccagac agtggagcca cagccacggc  1440

        ctacctgtgc ggggtcaagg caacttcca gaccattggc ttgagtgcag ccgcccgctt  1500

25      taaccagtgc aacacgacac gcggcaacga ggtcatctcc gtgatgaatc gggccaagaa  1560

        agcagggaag tcagtgggag tggtaaccac cacacgagtg cagcacgcct cgccagccgg  1620

        cacctacgcc cacacggtga accgcaactg gtactcggac gccgacgtgc ctgcctcggc  1680

        ccgccaggag gggtgccagg acatcgctac gcagctcatc tccaacatgg acattgacgt  1740

        gatcctaggt ggaggccgaa agtacatgtt tcgcatggga accccagacc ctgagtaccc  1800

30      agatgactac agccaaggtg ggaccaggct ggacgggaag aatctggtgc aggaatggct  1860

        ggcgaagcgc cagggtgccc ggtatgtgtg gaaccgcact gagctcatgc aggcttccct  1920

        ggaccgtct gtgacccatc tcatgggtct ctttgagcct ggagacatga atacgagat  1980

        ccaccgagac tccacactgg acccctccct gatggagatg acagaggctg ccctgcgcct  2040

        gctgagcagg aaccccgcg gcttcttcct cttcgtggag ggtggtcgca tcgaccatgg  2100
```

                                      29

```
tcatcatgaa agcagggctt accgggcact gactgagacg atcatgttcg acgacgccat 2160

tgagagggcg ggccagctca ccagcgagga ggacacgctg agcctcgtca ctgccgacca 2220

ctcccacgtc ttctccttcg gaggctaccc cctgcgaggg agctccatct tcgggctggc 2280

ccctggcaag gcccgggaca ggaaggccta cacggtcctc ctatacggaa acggtccagg 2340

ctatgtgctc aaggacggcg cccggccgga tgttaccgag agcgagagcg ggagccccga 2400

gtatcggcag cagtcagcag tgcccctgga cgaagagacc cacgcaggcg aggacgtggc 2460

ggtgttcgcg cgcggccgc aggcgcacct ggttcacggc gtgcaggagc agaccttcat 2520

agcgcacgtc atggccttcg ccgcctgcct ggagccctac accgcctgcg acctggcgcc 2580

ccccgccggc accaccgacg ccgcgcaccc gggttactct agagtcgggg cggccggccg 2640

cttcgagcag acatgataag atacattgat gagtttggac aaaccacaac tagaatggaa 2700

tgcctcgcgc tttctctctg ctcttgtttt tggtaagctg gagtcacggg agaccaggga 2760

ctctcaccct caccccagtg actcttaacc ggggtactcg acctgcagcc aagctagctt 2820

ggctggacgt aaactcctct tcagacctaa taacttcgta tagcatacat tatacgaagt 2880

tatattaagg gttattgaat atgatcggaa ttcctcgacg gatccgaaca aacgacccaa 2940

cacccgtgcg ttttattctg tcttttttatt gccgatcccc tcagaagaac tcgtcaagaa 3000

ggcgatagaa ggcgatgcgc tgcgaatcgg gagcggcgat accgtaaagc acgaggaagc 3060

ggtcagccca ttcgccgcca agctcttcag caatatcacg ggtagccaac gctatgtcct 3120

gatagcggtc cgccacaccc agccggccac agtcgatgaa tccagaaaag cggccatttt 3180

ccaccatgat attcggcaag caggcatcgc catgggtcac gacgagatcc tcgccgtcgg 3240

gcatgcgcgc cttgagcctg gcgaacagtt cggctggcgc gagcccctga tgctcttcgt 3300

ccagatcatc ctgatcgaca agaccggctt ccatccgagt acgtgctcgc tcgatgcgat 3360

gtttcgcttg gtggtcgaat gggcaggtag ccggatcaag cgtatgcagc cgccgcattg 3420

catcagccat gatggatact ttctcggcag gagcaaggtg agatgacagg agatcctgcc 3480

ccggcacttc gcccaatagc agccagtccc ttcccgcttc agtgacaacg tcgagcacag 3540

ctgcgcaagg aacgcccgtc gtggccagcc acgatagccg cgctgcctcg tcctgcagtt 3600

cattcagggc accggacagg tcggtcttga caaaaagaac cgggcgcccc tgcgctgaca 3660

gccggaacac ggcggcatca gagcagccga ttgtctgttg tgcccagtca tagccgaata 3720

gcctctccac ccaagcggcc ggagaacctg cgtgcaatcc atcttgttca atggccgatc 3780

ccatggtaaa aaccctcctc gcagggtcgc tcggtgttcg aggccacacg cgtcacctta 3840

atatgcgaag tggacctggg accgcgccgc cccgactgca tctgcgtgtt cgaattcgcc 3900

aatgacaaga cgctgggcgg ggtttgctcg acattgggtg gaaacattcc aggcctgggt 3960

ggagaggctt tttgcttcct cttgcaaaac cacactgctc gacattgggt ggaaacattc 4020

caggcctggg tggagaggct ttttgcttcc tcttgaaaac cacactgctc gacctgcagc 4080

caagctagct tggctggacg taaactcctc ttcagaccta ataacttcgt atagcataca 4140
```

```
ttatacgaag ttatattaag ggttattgaa tatgatcgga attcctcgat taagagcagg 4200
atattttgtt gtgtgggggct ttctgtgcgt tatatggtga ttagcagaac tgatgacctc 4260
cctgcagggt tctgccttgt ggtgggaagg gtggattta agtgctttgt gaagagtcgt 4320
tcatctggct cctgaaaggg ggctcaaaca ggcaccacgt agcatccaat gaagtttgct 4380
ttctctgact tccattgtac tgtgaggttg gaatataaca ttgcggttgc cataaggcac 4440
caccagataa tggcacacgg tgatatatag aaattctagc cccttgagat gatcctcttc 4500
ttacttttaa aatcaatagt ttgaaccaac aaaaggaccc tataaaccaa aagcaagaca 4560
acacgattca ggactaaact ttgctatctc tttcttgacc caatccagtt ctcctcgctg 4620
gagagagcac agcttggtac tacaatgcct ccagtgagct catgacgtat gatgaagcca 4680
gtgcatactg tcagcgggac tacacacatc tggtggcaat tcagaacaag gaagagatca 4740
actaccttaa ctccaatctg aaacattcac cgagttacta ctggattgga atcagaaaag 4800
tcaataacgt atggatctgg gtggggacgg ggaagcctct gacagaggaa gctcagaact 4860
gggctccagg tgaaccaaac aacaaacaaa gaaatgagga ctgtgtagag atttacatcc 4920
aacgaaccaa agactcgggc atgtggaatg acgagagatg taacaaaaag aagctggctc 4980
tgtgctacac aggtatgaag tttctgcatg gtggaaggct ggctctgtgt ggaggcagcc 5040
tgacagattg agagttgtat aaaggaattg gtctctacta gttttttcaa agagatgatt 5100
ataagtgatt ttaatagtaa ttgcatctct tagtactgat ttgtgtgagt agaggcaaga 5160
tatatacata tatgtgtgtg tgtatgtatg tacttatatg tatacatata ataattctat 5220
caatatacag agtatatata tttgcataaa aataaaatat gtggtttagt tgtagctatt 5280
ctgatgtgta tttattacca ccaaaatata caacagatga gactggaact tgtatctggc 5340
atgccaatca aaatctccag cactaatgtc attagagtca tctggattgc actgattcta 5400
aattacaaac aaacaaactc atgatgagca ccatactaat tgactgtcct catatggact 5460
gtgttttctg tagcttcgtg taccaatgca tcctgcagtg gtcatggtga atgcatagag 5520
accatcaata gttacacctg caagtgccac cctggcttcc tgggacccaa ctgtgagcaa 5580
ggtaagtctt gtcctcacct gtttcttctc caagatggta acaccctctc ctcccccaga 5640
tggcttgtga tggcttgtca gtcgggccca tgtgtttcct ctactgagta agagtgatat 5700
agtggctgag actatgagat cagatcctcc tgggtcaaac tgcagaccta ctaccgtat 5760
tacttatggc accttgacaa agtagtcctg tagggtgact gacgattcca gttgtcatga 5820
aactaaataa catcatgtgg caattagctg aagcttagcg ttttagttcc agagaacgac 5880
aaagaaactg tttcatagtc tgatggttcc atagagcctg gaccacagga aatgttcaat 5940
gggtgataat tatggtgacc agcgttcctc tctcagatgc aaagggagag atgagcagac 6000
gtgtgtcttg attcgttgtt ttgtttgatt tttcagctgt gacttgcaaa ccacaggaac 6060
accctgacta tggaagcctg aactgctccc acccgttcgg ccccttcagc tataattcct 6120
cctgctcctt tggctgtaaa aggggctacc tgcccagcag catggagacc accgtgcggt 6180
```

31

```
gtacgtcctc tggagagtgg agtgcgcctg ctccagcctg ccatggtaac tctcccaatg 6240
cagtaaacct cttcactcct cctcattgcc ttaatcgaat tcctgcagcc cgggggatcc 6300
actagttcta gagc                                                  6314
```

```
<210> 11
<211> 5083
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:DNA construct

<400> 11
```

```
ttagcatata atcagcggtc taggtcacta agtaggtact gtgtcactac agataccata 60
ttaccactgt tgaaacgaga aatctagtat gaatagaaca tgagaagaaa cattcaggaa 120
tgactcccct gcaccccagt gcctgttagg atggcctaag gtagcagtga ctgagcagaa 180
ccttggcact gatgtacgta tcatcaacag ttatccacaa gaaaatcgag agtgacagat 240
catgggtaat aaaatactct tagtttgctc atctttgtga aaccaagttc tacacttgat 300
```

```
tgataatggt aattagactt tataacacaa gacttaacat cacacacttg tatcccattt 360
gataaaactg catacaaata taagagccca gaaaagaat taatttagag gggcagagtc 420
tctgacatca ctatgaaagt gttttaactc agtggatatt cccagaaaac ttttggatg 480
cagttgagaa tttcctctta gccagatttt gataataatg tcctatgact cacaggaagc 540
cagctccct ataaagaggc tccagcagaa gcagtgctca gtggtcctcg actgactaca 600
```

```
cagcaaaact gcgagaagaa cggatagaga gaagcaggag caatacacct aagggatcca 660
acgccagaac aacaattcca ctgaacagta agtgcggatt ccgaaccaga ggagccttgg 720
gcccgaagca tagatttatg tgtgctcaca tacgcaaaaa aaaaaaaaa aagtcattct 780
gattaaaaaa gacctgtcta aactgttata gtgttgtaat taatacctac attttctctt 840
tgtttaaaat gatggaaatc ttaaagtctg catttattct ccatgctaga tgcctgtgaa 900
```

```
ataagggatg aggtacagga ttctaaaacc tcacagcttt gacttaaatg ctgttgtaga 960
aggatgtgag taacccgcac ttagaatttc cttctgtgac taattctgca ctttctctcc 1020
tcaggaaagt ttctccagtc tagcgcctgg atgaaagcaa ctgctggagt caattcgccc 1080
accatgctgc tgctgctgct gctgctgggc ctgaggctac agctctccct gggcatcatc 1140
ccagttgagg aggagaaccc ggacttctgg aaccgcgagg cagccgaggc cctgggtgcc 1200
```

Case 31176/A

```
gccaagaagc tgcagcctgc acagacagcc gccaagaacc tcatcatctt cctgggcgat 1260

gggatggggg tgtctacggt gacagctgcc aggatcctaa aagggcagaa gaaggacaaa 1320

ctggggcctg agatacccct ggccatggac cgcttcccat atgtggctct gtccaagaca 1380

tacaatgtag acaaacatgt gccagacagt ggagccacag ccacggccta cctgtgcggg 1440

gtcaagggca acttccagac cattggcttg agtgcagccg cccgctttaa ccagtgcaac 1500

acgacacgcg gcaacgaggt catctccgtg atgaatcggg ccaagaaagc agggaagtca 1560

gtgggagtgg taaccaccac acgagtgcag cacgcctcgc cagccggcac ctacgcccac 1620

acggtgaacc gcaactggta ctcggacgcc gacgtgcctg cctcggcccg ccaggagggg 1680

tgccaggaca tcgctacgca gctcatctcc aacatggaca ttgacgtgat cctaggtgga 1740

ggccgaaagt acatgtttcg catgggaacc ccagaccctg agtacccaga tgactacagc 1800

caaggtggga ccaggctgga cgggaagaat ctggtgcagg aatggctggc gaagcgccag 1860

ggtgcccggt atgtgtggaa ccgcactgag ctcatgcagg cttccctgga cccgtctgtg 1920

acccatctca tgggtctctt tgagcctgga gacatgaaat acgagatcca ccgagactcc 1980

acactggacc cctccctgat ggagatgaca gaggctgccc tgcgcctgct gagcaggaac 2040

ccccgcggct tcttcctctt cgtggagggt ggtcgcatcg accatggtca tcatgaaagc 2100

agggcttacc gggcactgac tgagacgatc atgttcgacg acgccattga gagggcgggc 2160

cagctcacca gcgaggagga cacgctgagc ctcgtcactg ccgaccactc ccacgtcttc 2220

tccttcggag ctacccccct gcgagggagc tccatcttcg ggctggcccc tggcaaggcc 2280

cgggacagga aggcctacac ggtcctccta tacggaaacg gtccaggcta tgtgctcaag 2340

gacggcgccc ggccggatgt taccgagagc gagagcggga gccccgagta tcggcagcag 2400

tcagcagtgc ccctggacga agagacccac gcaggcgagg acgtggcggt gttcgcgcgc 2460

ggcccgcagg cgcacctggt tcacggcgtg caggagcaga ccttcatagc gcacgtcatg 2520

gccttcgccg cctgcctgga gccctacacc gcctgcgacc tggcgccccc cgccggcacc 2580

accgacgccg cgcacccggg ttactctaga gtcggggcgg ccggccgctt cgagcagaca 2640

tgataagata cattgatgag tttggacaaa ccacaactag aatgcagtga aaaaaatgct 2700

ttatttgtga aatttgtgat gctattgctt tatttgtaac cattataagc tgcaataaac 2760

aagttaacaa caacaattga atgcctcgcg ctttctctct gctcttgttt ttggtaagct 2820

ggagtcacgg gagaccaggg actctcaccc tcaccccagt gactcttaac cggggtactc 2880

gacctgcagc caagctagct ggctggacg taaactcctc ttcagaccta ataacttcgt 2940

atagcataca ttatacgaag ttatattaag ggttattgaa tatgatcgga attcctcgat 3000

taagagcagg atattttgtt gtgtggggct ttctgtgcgt tatatggtga ttagcagaac 3060

tgatgacctc cctgcagggt tctgccttgt ggtgggaagg gtggatttta agtgctttgt 3120

gaagagtcgt tcatctggct cctgaaaggg ggctcaaaca ggcaccacgt agcatccaat 3180

gaagtttgct ttctctgact tccattgtac tgtgaggttg gaatataaca ttgcggttgc 3240
```

33

```
cataaggcac caccagataa tggcacacgg tgatatatag aaattctagc cccttgagat 3300
gatcctcttc ttacttttaa aatcaatagt ttgaaccaac aaaaggaccc tataaaccaa 3360
aagcaagaca acacgattca ggactaaact ttgctatctc tttcttgacc caatccagtt 3420
ctcctcgctg gagagagcac agcttggtac tacaatgcct ccagtgagct catgacgtat 3480
gatgaagcca gtgcatactg tcagcgggac tacacacatc tggtggcaat tcagaacaag 3540
gaagagatca actaccttaa ctccaatctg aaacattcac cgagttacta ctggattgga 3600
atcagaaaag tcaataacgt atggatctgg gtgggacgg ggaagcctct gacagaggaa 3660
gctcagaact gggctccagg tgaaccaaac aacaaacaaa gaaatgagga ctgtgtagag 3720
atttacatcc aacgaaccaa agactcgggc atgtggaatg acgagagatg taacaaaaag 3780
aagctggctc tgtgctacac aggtatgaag tttctgcatg gtggaaggct ggctctgtgt 3840
ggaggcagcc tgacagattg agagttgtat aaaggaattg gtctctacta gtttttcaa 3900
agagatgatt ataagtgatt ttaatagtaa ttgcatctct tagtactgat ttgtgtgagt 3960
agaggcaaga tatatacata tatgtgtgtg tgtatgtatg tacttatatg tatacatata 4020
ataattctat caatatacag agtatatata tttgcataaa aataaaatat gtggtttagt 4080
tgtagctatt ctgatgtgta tttattacca ccaaaatata caacagatga gactggaact 4140
tgtatctggc atgccaatca aaatctccag cactaatgtc attagagtca tctggattgc 4200
actgattcta aattacaaac aaacaaactc atgatgagca ccatactaat tgactgtcct 4260
catatggact gtgttttctg tagcttcgtg taccaatgca tcctgcagtg gtcatggtga 4320
atgcatagag accatcaata gttacacctg caagtgccac cctggcttcc tgggacccaa 4380
ctgtgagcaa ggtaagtctt gtcctcacct gtttcttctc caagatggta acaccctctc 4440
ctcccccaga tggcttgtga tggcttgtca gtcgggccca tgtgtttcct ctactgagta 4500
agagtgatat agtggctgag actatgagat cagatcctcc tgggtcaaac tgcagaccta 4560
ctacccgtat tacttatggc accttgacaa agtagtcctg tagggtgact gacgattcca 4620
gttgtcatga aactaaataa catcatgtgg caattagctg aagcttagcg ttttagttcc 4680
agagaacgac aaagaaactg tttcatagtc tgatggttcc atagagcctg gaccacagga 4740
aatgttcaat gggtgataat tatggtgacc agcgttcctc tctcagatgc aaagggagag 4800
atgagcagac gtgtgtcttg attcgttgtt ttgtttgatt tttcagctgt gacttgcaaa 4860
ccacaggaac accctgacta tggaagcctg aactgctccc acccgttcgg cccttcagc 4920
tataattcct cctgctcctt tggctgtaaa aggggctacc tgcccagcag catggagacc 4980
accgtgcggt gtacgtcctc tggagagtgg agtgcgcctg ctccagcctg ccatggtaac 5040
tctcccaatg cagtaaacct cttcactcct cctcattgcc tta                5083
```

<210> 12

<211> 4989

<212> DNA

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence:DNA construct

<400> 12

```
ttagcatata atcagcggtc taggtcacta agtaggtact gtgtcactac agataccata 60
ttaccactgt tgaaacgaga aatctagtat gaatagaaca tgagaagaaa cattcaggaa 120
tgactcccct gcaccccagt gcctgttagg atggcctaag gtagcagtga ctgagcagaa 180
ccttggcact gatgtacgta tcatcaacag ttatccacaa gaaaatcgag agtgacagat 240
catgggtaat aaaatactct tagtttgctc atctttgtga aaccaagttc tacacttgat 300
tgataatggt aattagactt tataacacaa gacttaacat cacacacttg tatcccattt 360
gataaaactg catacaaata taagagccca gaaaaagaat taatttagag gggcagagtc 420
tctgacatca ctatgaaagt gttttaactc agtggatatt cccagaaaac tttttggatg 480
cagttgagaa tttcctctta gccagatttt gataataatg tcctatgact cacaggaagc 540
cagctcccct ataaagaggc tccagcagaa gcagtgctca gtggtcctcg actgactaca 600
cagcaaaact gcgagaagaa cggatagaga gaagcaggag caatacacct aagggatcca 660
acgccagaac aacaattcca ctgaacagta agtgcggatt ccgaaccaga ggagccttgg 720
gcccgaagca tagatttatg tgtgctcaca tacgcaaaaa aaaaaaaaaa aagtcattct 780
gattaaaaaa gacctgtcta aactgttata gtgttgtaat taatacctac attttctctt 840
tgtttaaaat gatggaaatc ttaaagtctg catttattct ccatgctaga tgcctgtgaa 900
ataagggatg aggtacagga ttctaaaacc tcacagcttt gacttaaatg ctgttgtaga 960
aggatgtgag taacccgcac ttagaatttc cttctgtgac taattctgca ctttctctcc 1020
tcaggaaagt ttctccagtc tagcgcctgg atgaaagcaa ctgctggagt caattcgccc 1080
accatgctgc tgctgctgct gctgctgggc ctgaggctac agctctccct gggcatcatc 1140
ccagttgagg aggagaaccc ggacttctgg aaccgcgagg cagccgaggc cctgggtgcc 1200
gccaagaagc tgcagcctgc acagacagcc gccaagaacc tcatcatctt cctgggcgat 1260
gggatggggg tgtctacggt gacagctgcc aggatcctaa aagggcagaa gaaggacaaa 1320
ctggggcctg agatacccct ggccatggac cgcttcccat atgtggctct gtccaagaca 1380
tacaatgtag acaaacatgt gccagacagt ggagccacag ccacggccta cctgtgcggg 1440
gtcaagggca acttccagac cattggcttg agtgcagccg cccgctttaa ccagtgcaac 1500
acgacacgcg gcaacgaggt catctccgtg atgaatcggg ccaagaaagc agggaagtca 1560
```

35

Case 31176/A

```
gtgggagtgg taaccaccac acgagtgcag cacgcctcgc cagccggcac ctacgccac 1620

acggtgaacc gcaactggta ctcggacgcc gacgtgcctg cctcggcccg ccaggagggg 1680

tgccaggaca tcgctacgca gctcatctcc aacatggaca ttgacgtgat cctaggtgga 1740

ggccgaaagt acatgtttcg catgggaacc ccagaccctg agtacccaga tgactacagc 1800

caaggtggga ccaggctgga cgggaagaat ctggtgcagg aatggctggc gaagcgccag 1860

ggtgcccggt atgtgtggaa ccgcactgag ctcatgcagg cttccctgga cccgtctgtg 1920

acccatctca tgggtctctt tgagcctgga gacatgaaat acgagatcca ccgagactcc 1980

acactggacc cctccctgat ggagatgaca gaggctgccc tgcgcctgct gagcaggaac 2040

ccccgcggct tcttcctctt cgtggagggt ggtcgcatcg accatggtca tcatgaaagc 2100

agggcttacc gggcactgac tgagacgatc atgttcgacg acgccattga gagggcgggc 2160

cagctcacca gcgaggagga cacgctgagc ctcgtcactg ccgaccactc ccacgtcttc 2220

tccttcggag gctacccccct gcgagggagc tccatcttcg ggctggcccc tggcaaggcc 2280

cgggacagga aggcctacac ggtcctccta tacggaaacg gtccaggcta tgtgctcaag 2340

gacggcgccc ggccggatgt taccgagagc gagagcggga gccccgagta tcggcagcag 2400

tcagcagtgc ccctggacga agagacccac gcaggcgagg acgtggcggt gttcgcgcgc 2460

ggcccgcagg cgcacctggt tcacggcgtg caggagcaga ccttcatagc gcacgtcatg 2520

gccttcgccg cctgcctgga gccctacacc gcctgcgacc tggcgccccc cgccggcacc 2580

accgacgccg cgcacccggg ttactctaga gtcggggcgg ccggccgctt cgagcagaca 2640

tgataagata cattgatgag tttggacaaa ccacaactag aatggaatgc ctcgcgcttt 2700

ctctctgctc ttgttttggg taagctggag tcacgggaga ccagggactc tcaccctcac 2760

cccagtgact cttaaccggg gtactcgacc tgcagccaag ctagcttggc tggacgtaaa 2820

ctcctcttca gacctaataa cttcgtatag catacattat acgaagttat attaagggtt 2880

attgaatatg atcggaattc ctcgattaag agcaggatat tttgttgtgt ggggctttct 2940

gtgcgttata tggtgattag cagaactgat gacctccctg cagggttctg ccttgtggtg 3000

ggaagggtgg attttaagtg ctttgtgaag agtcgttcat ctggctcctg aaaggggggct 3060

caaacaggca ccacgtagca tccaatgaag tttgctttct ctgacttcca ttgtactgtg 3120

aggttggaat ataacattgc ggttgccata aggcaccacc agataatggc acacggtgat 3180

atatagaaat tctagcccct tgagatgatc ctcttcttac ttttaaaatc aatagtttga 3240

accaacaaaa ggaccctata aaccaaaagc aagacaacac gattcaggac taaactttgc 3300

tatctctttc ttgacccaat ccagttctcc tcgctggaga gagcacagct tggtactaca 3360

atgcctccag tgagctcatg acgtatgatg aagccagtgc atactgtcag cgggactaca 3420

cacatctggt ggcaattcag aacaaggaag agatcaacta ccttaactcc aatctgaaac 3480

attcaccgag ttactactgg attggaatca gaaaagtcaa taacgtatgg atctgggtgg 3540

ggacggggaa gcctctgaca gaggaagctc agaactgggc tccaggtgaa ccaaacaaca 3600
```

36

```
aacaaagaaa tgaggactgt gtagagattt acatccaacg aaccaaagac tcgggcatgt 3660

ggaatgacga gagatgtaac aaaaagaagc tggctctgtg ctacacaggt atgaagtttc 3720

tgcatggtgg aaggctggct ctgtgtggag gcagcctgac agattgagag ttgtataaag 3780

gaattggtct ctactagttt tttcaaagag atgattataa gtgattttaa tagtaattgc 3840

atctcttagt actgatttgt gtgagtagag gcaagatata tacatatatg tgtgtgtgta 3900

tgtatgtact tatatgtata catataataa ttctatcaat atacagagta tatatatttg 3960

cataaaaata aaatatgtgg tttagttgta gctattctga tgtgtatttta ttaccaccaa 4020

aatatacaac agatgagact ggaacttgta tctggcatgc caatcaaaat ctccagcact 4080

aatgtcatta gagtcatctg gattgcactg attctaaatt acaaacaaac aaactcatga 4140

tgagcaccat actaattgac tgtcctcata tggactgtgt tttctgtagc ttcgtgtacc 4200

aatgcatcct gcagtggtca tggtgaatgc atagagacca tcaatagtta cacctgcaag 4260

tgccaccctg gcttcctggg acccaactgt gagcaaggta agtcttgtcc tcacctgttt 4320

cttctccaag atggtaacac cctctcctcc cccagatggc ttgtgatggc ttgtcagtcg 4380

ggcccatgtg tttcctctac tgagtaagag tgatatagtg gctgagacta tgagatcaga 4440

tcctcctggg tcaaactgca gacctactac ccgtattact tatggcacct tgacaaagta 4500

gtcctgtagg gtgactgacg attccagttg tcatgaaact aaataacatc atgtggcaat 4560

tagctgaagc ttagcgtttt agttccagag aacgacaaag aaactgtttc atagtctgat 4620

ggttccatag agcctggacc acaggaaatg ttcaatgggt gataattatg gtgaccagcg 4680

ttcctctctc agatgcaaag ggagagatga gcagacgtgt gtcttgattc gttgtttttgt 4740

ttgattttttc agctgtgact tgcaaaccac aggaacaccc tgactatgga agcctgaact 4800

gctcccaccc gttcggcccc ttcagctata attcctcctg ctcctttggc tgtaaaaggg 4860

gctacctgcc cagcagcatg gagaccaccg tgcggtgtac gtcctctgga gagtggagtg 4920

cgcctgctcc agcctgccat ggtaactctc ccaatgcagt aaacctcttc actcctcctc 4980

attgcctta                                                           4989
```